Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215052 | 0.85 | ALDH1A1 (0.75) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8790687 | 0.83 | ALDH1A1 (0.67) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3708995 | 0.81 | HPGD (0.65) | HPGDSMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL13753317 | 0.81 | ALDH1A1 (0.73) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28835294 | 0.81 | ALDH1A1 (0.63) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24426002 | 0.80 | ALDH1A1 (0.76) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6429154 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2112079 | 0.78 | ALDH1A1 (0.69) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6360984 | 0.78 | ALDH1A1 (0.80) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5717558 | 0.77 | ALDH1A1 (0.73) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110097320-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| EP-2054063-A2 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Concert Pharmaceuticals Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008024439-A2 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097320-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | ERBB2, ERBB4, EGFR | ALDH1A1 3251/4885HPGD 2036/4885MEN1 2650/4885 |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | ERBB2, ERBB4, EGFR | ALDH1A1 3251/4885HPGD 2036/4885MEN1 2650/4885 |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | ERBB2, ERBB4, EGFR | ALDH1A1 3240/4885HPGD 2348/4885MEN1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.